EIF3J and central nervous system cancer: To clarify the expression of EIF3J-AS1 in glioma patients, we analyzed the CGGA database showed that EIF3J-AS1 expression was highest in WHO grade II gliomas but decreased with increasing tumor grade (Fig. 1A).